ClinicalTrials.gg
CompletedNCT07929896Updated Nov 10, 2026

Evaluation Of New Shape of 3D Bone Plate in the Treatment of Posterior Mandibular Fractures

An interventional study of ORIF using Pin Buckle bone plate and ORIF using conventional two miniplates in Posterior Mandibular Fractures Involving the Body or Angle Region, sponsored by Suez Canal University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Suez Canal University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2025, registered Oct 2026).
Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

comparing new design of 3D titanium bone plate with less number of screws with conventional two miniplates in the treatment of posterior mandibular fractures involving the body or angle region

02

Conditions studied

  • Posterior Mandibular Fractures Involving the Body or Angle Region

Browse trials for

03

In context

Mandibular Fractures

91 studies on the registry are indexed under Mandibular Fractures; 24 are open to participants now.

This study's enrollment of 20 is close to the median of 21 across 72 interventional studies indexed under Mandibular Fractures.

Browse Mandibular Fractures studies →

Lead sponsor

Suez Canal University is the lead sponsor of 164 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 to 60 years old.
  • Adult patients of both genders.
  • Patients classified as (ASA) physical status I.
  • Patients presenting with simple unilateral posterior mandibular fractures involving the mandibular body or angle requiring open reduction and internal fixation.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • ,III,IV
  • Patients with associated maxillofacial injuries that may interfere with study outcomes.
  • Patients with comminuted mandibular fractures that requires reconstruction plate
  • Patients with infected fractures.
  • Patients with pathological fractures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Pin Buckle (study) group

    ten patients with posterior mandibular fractures involving the body or angle region, were treated with pin buckle bone plate

    Procedure: ORIF using Pin Buckle bone plate

  • Active comparator
    conventional two miniplates (control) group

    ten patients with posterior mandibular fractures involving the body or angle region, were treated with conventional two miniplates

    Procedure: ORIF using conventional two miniplates

Interventions

  • ProcedureORIF using Pin Buckle bone plate

    open reduction and internal fixation

  • ProcedureORIF using conventional two miniplates

    Open Reduction and Internal Fixation

06

What researchers measure

Primary outcomes

  1. Change in Radiographic Fracture-Line Width

    The width of the fracture line will be measured in millimeters using DIGORA image analysis software on standardized digital panoramic radiographs. Measurements will be performed at three standardized points (superior, middle, and inferior) along the visible fracture line, and the mean value will be calculated. Changes from baseline will be assessed at 3 and 6 months postoperatively and compared between the study and control groups.

    Time frame: Immediately postoperatively (baseline), 3 months, and 6 months postoperatively.

Secondary outcomes

  1. Change in Radiographic Bone Density at the Fracture Site

    Radiographic bone healing will be assessed by measuring the mean grayscale value at the fracture site using DIGORA image analysis software on standardized digital panoramic radiographs. Measurements will be performed using a standardized region of interest (ROI) at the immediate postoperative baseline, 3 months, and 6 months postoperatively. The change in mean grayscale values from baseline to 3 and 6 months will be evaluated and compared between the study and control groups.

    Time frame: Immediately postoperatively (baseline), 3 months, and 6 months postoperatively.

  2. Postoperative Pain Intensity

    Postoperative pain intensity will be evaluated using a 10-cm Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable). Patients will be asked to indicate their pain intensity at each follow-up assessment. Pain scores will be compared between the study and control groups.

    Time frame: Postoperative days 1, 7, and 14.

  3. Postoperative Facial Edema

    Facial edema will be assessed using standardized tape measurements between two anatomical landmarks: the tragus and corner of the mouth, and the lateral canthus and gonion. The sum of the two measurements will be calculated. Changes in the summed measurements relative to the preoperative baseline will be used to evaluate postoperative facial edema and compared between the study and control groups.

    Time frame: Preoperatively (baseline) and postoperative days 1, 7, and 14.

  4. Postoperative Wound Healing

    Wound healing will be evaluated clinically using a structured scoring system consisting of five parameters: wound size reduction, tissue appearance, wound exudate, pain and inflammatory response, and mucosal integrity. Each parameter will be scored from 0 (poor) to 2 (good), resulting in a total score ranging from 0 to 10, with higher scores indicating better wound healing. Total wound healing scores will be compared between the study and control groups.

    Time frame: Postoperative days 1, 7, and 14.

  5. Clinical Stability of Fracture Segments

    Fracture stability will be assessed by bimanual digital palpation to detect mobility between fracture segments during functional mandibular movements and manual manipulation. Fractures will be classified as stable (absence of detectable movement) or unstable (presence of detectable movement). The proportion of stable fractures will be compared between the study and control groups.

    Time frame: Immediately postoperatively and 6 months postoperatively.

07

Study locations

1 site
  • Faculty of Dentistry / Suez Canal University
    Ismailia, Ismailia Governorate 41511, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 7 months.

Of 38 non-industry interventional studies with no phase under Mandibular Fractures, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 38 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 10, 2026
StartActual
Jul 18, 2025
Primary completionActual
Mar 10, 2026
CompletionActual
Sep 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07929896
Responsible party
Ahmed fathy (Principal investigator, Suez Canal University) — Principal investigator
First posted
Nov 10, 2026
Start date
Jul 18, 2025
Primary completion
Mar 10, 2026
Completion
Sep 10, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion